XORTX Therapeutics
XRTX
2 hedge funds and large institutions have $416 invested in XORTX Therapeutics in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
1.78% less ownership
Funds ownership: 1.78% → 0% (-1.8%)
67% less funds holding
Funds holding: 6 → 2 (-4)
100% less capital invested
Capital invested by funds: $324K → $416 (-$324K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$299K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$19.7K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.43K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
1
Clearstead Advisors
Cleveland,
Ohio
| $266 | – | – | – |
|
|
2
National Bank of Canada
Montreal,
Quebec, Canada
| $150 | -$1.43K | -288 | -89% |
|
|
AC
3
Armistice Capital
New York
| – | -$299K | -53,000 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$19.7K | -3,486 | Closed |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -299 | Closed |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.3K | -231 | Closed |
|
XRTX Hedge Fund Activity: Q1 2025 in Review
2 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2025, worth a combined $416 — down 100% from $324K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of XRTX and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $299K sold.
- 2 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2025, down from 6 in Q4 2024.
- Funds reported $416 of XORTX Therapeutics stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new XORTX Therapeutics positions in Q1 2025 and 4 closed out, a net change of -4 holders.
- The largest XORTX Therapeutics seller in Q1 2025 was Armistice Capital, an estimated $299K sold.
Based on aggregated 13F filings for Q1 2025.